1
2
3
4
5
6
7
8
9
HAEGARDA
223 DAYS. 0 ATTACKS.
The Right Therapy Matters
The Challenge.
HAEGARDA is the only subcutaneous C1-INH preventive therapy for a rare, genetic disease called hereditary angioedema (HAE). Many HAE patients and HCPs struggle to find a therapy solution that provides the efficacy patients can feel confident about. They’re looking for a therapy they can rely on.
The Solution.
We created a campaign that brought efficacy to the forefront in both a compassionate and data driven way. By highlighting the number of calendar days one could go without an attack and illustrating how time could be spent, we showed what strong efficacy could provide. By pairing copy that reinforces the patient’s worth and highlighting the possibilities with images of everyday enjoyment, patients see a life with HAE doesn’t need to be a life burdened by HAE.